ArticleNeuro-oncology2023
Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups.
Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Prognostic revalidation of RANO categories for extent of resection in glioblastoma: a reconstruction of individual patient data.Journal of neuro-oncology · 2025Pooled it
- Comparative efficacy of awake and asleep motor mapping in glioma surgery: A meta-analysis of 3011 patients.Neurosurgical review · 2024Pooled it
- A Permanent but Not Transient Postoperative Deficit Has Impact on OS and PFS in IDHwt-Glioma Patients.Journal of clinical medicine · 2026Article
- Extent of resection and survival in IDH-wildtype glioblastoma: interaction with MGMT status and chemoradiation.Journal of neuro-oncology · 2026Article
- Intraoperative technological advances and new frontiers in precision glioma surgery.Journal of neuro-oncology · 2026Review
- Intraoperative functional brain mapping for glioma surgery: a comprehensive review of the University of California San Francisco mapping protocol.Journal of neuro-oncology · 2026Review
- Butterfly gliomas: to biopsy or to ablate - a longitudinal cohort study.Journal of neuro-oncology · 2026Article
- Article
- Article
- Review
- Patterns and quality of therapeutic care for glioma: a population-based study in Belgium between 2016 and 2019.ESMO open · 2026Article
- Machine Learning-Based Fluorescence Assessment for Augmented Imaging and Decision Support in Glioblastoma Resections.Cancers · 2026Article
- Two-Stage Surgery in Patients with Diffuse Glioma-Indications, Implications and Outcome.Cancers · 2026Article
- Cerebrospinal fluid cfDNA-based molecular assessment of resection extent and prognosis in glioma.Communications medicine · 2026Article
- The Dual Impact of Glioma Resection on Survival and Health-Related Quality of Life: Resect More, Live Better.Brain tumor research and treatment · 2026Article
- Eloquent glioma resection assisted by brain connectomics: A new tool for awake neurosurgery.Surgical neurology international · 2026Article
- Clinical outcomes of early salvage surgery for residual or enlarging contrast-enhancing lesions after radiotherapy in patients with glioblastoma.Frontiers in oncology · 2026Article
- Article
- Article
- Molecular-based decision-making in glioblastoma surgery: When to aim for supramaximal resection.Neuro-oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of extent of resection (EOR), residual tumor volume (RTV), and gross-total resection (GTR) in glioblastoma subgroups is currently unknown. This study aimed to analyze their impact on patient subgroups in relation to neurological and functional outcomes.
methodsPatients with tumor resection for eloquent glioblastoma between 2010 and 2020 at 4 tertiary centers were recruited from a cohort of 3919 patients.
resultsOne thousand and forty-seven (1047) patients were included. Higher EOR and lower RTV were significantly associated with improved overall survival (OS) and progression-free survival (PFS) across all subgroups, but RTV was a stronger prognostic factor. GTR based on RTV improved median OS in the overall cohort (19.0 months, P < .0001), and in the subgroups with IDH wildtype tumors (18.5 months, P = .00055), MGMT methylated tumors (35.0 months, P < .0001), aged <70 (20.0 months, P < .0001), NIHSS 0-1 (19.0 months, P = .0038), KPS 90-100 (19.5 months, P = .0012), and KPS ≤80 (17.0 months, P = .036). GTR was significantly associated with improved OS in the overall cohort (HR 0.58, P = .0070) and improved PFS in the NIHSS 0-1 subgroup (HR 0.47, P = .012). GTR combined with preservation of neurological function (OFO 1 grade) yielded the longest survival times (median OS 22.0 months, P < .0001), which was significantly more frequently achieved in the awake mapping group (50.0%) than in the asleep group (21.8%) (P < .0001).
conclusionsMaximum resection was especially beneficial in the subgroups aged <70, NIHSS 0-1, and KPS 90-100 without increasing the risk of postoperative NIHSS or KPS worsening. These findings may assist surgical decision making in individual glioblastoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.